Results 1 to 10 of about 32,676 (224)
Drugs of Today, 2007 There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +3 more sources
Diabetes & Vascular Disease Research, 2022 Purpose Combination of Rivaroxaban plus Aspirin improved cardiovascular outcome in patients with stable cardiovascular disease. The aim was to determine if Rivaroxaban and acetylsalicylic acid alone or in combination may protect mitochondrial mitophagy ...
Khaoula Zekri-Nechar +7 more
doaj +2 more sources
Rivaroxaban and Hemostasis in Emergency Care
Emergency Medicine International, 2014 Rivaroxaban is an oral, direct Factor Xa inhibitor, approved for the prevention and treatment of several thromboembolic disorders. Rivaroxaban does not require routine coagulation monitoring and has a short half-life. However, confirmation of rivaroxaban
Jürgen Koscielny, Edita Rutkauskaite
doaj +2 more sources
Clinical Medicine Insights: Case Reports, 2015 Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an accidental overdose in a patient with pulmonary thromboembolism, when the patient ...
Dimitar Sajkov, Alexander Gallus
doaj +2 more sources
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
Therapeutics and Clinical Risk Management, 2014 Alexander GG Turpie Department of Medicine, McMaster University, Hamilton, ONT, Canada Abstract: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke ...
Turpie AGG
doaj +1 more source
Rivaroxaban postmarketing risk of liver injury [PDF]
Journal of Hepatology, 2014 BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders.
Stefan Russmann +2 more
exaly +2 more sources
Frontiers in Pharmacology, 2021 Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion.
Rui-juan Xu +5 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Peritoneovenous shunts (PVSs) are used to relieve ascites in cirrhosis. Disseminated intervascular coagulation (DIC) is a complication of PVSs requiring immediate PVS removal.
Fabienne Lucas +4 more
doaj +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. Objectives To demonstrate and compare menstrual patterns and actions taken
Kochawan Boonyawat +9 more
doaj +1 more source
Clinical and Translational Science, 2022 Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade through directly inactivating factors Xa. Despite rivaroxaban is widely used for prevention and treatment of venous thrombosis, and its common adverse reactions ...
Ming Zhao +8 more
doaj +1 more source